Stock events for Traws Pharma, Inc. (TRAW)
As of September 30, 2025, Traws Pharma, Inc. reported cash and cash equivalents of $6.4 million, with an accumulated deficit of $632.5 million, and there is substantial doubt about the company's ability to continue as a going concern for more than one year without additional funding. The net income for the nine months ended September 30, 2025, was $16.6 million, a significant improvement from a net loss of $136.6 million for the same period in 2024. Revenue for the nine months ended September 30, 2025, increased to $2.8 million from $0.2 million in 2024, primarily due to the recognition of deferred revenue from a terminated agreement with SymBio. Operating expenses and research and development expenses decreased significantly. The company is actively exploring various funding sources to support its ongoing clinical development and regulatory approvals.
Demand Seasonality affecting Traws Pharma, Inc.’s stock price
The provided search results do not contain specific information regarding the demand seasonality for Traws Pharma, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to development milestones, licensing agreements, and potential future product commercialization rather than direct consumer demand with seasonal fluctuations.
Overview of Traws Pharma, Inc.’s business
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule oral product candidates for respiratory viral diseases and cancer. The company's major product candidates include TRX01 (Ratutrelvir) for COVID-19, Tivoxavir marboxil for bird flu and seasonal influenza, Narazaciclib for solid tumors and hematological malignancies, and Rigosertib for various cancers. The company was formerly known as Onconova Therapeutics, Inc. and officially changed its name to Traws Pharma, Inc. in April 2024.
TRAW’s Geographic footprint
Traws Pharma, Inc. is headquartered in Newtown, Pennsylvania, United States. Specific details about its broader geographic footprint for product distribution or clinical trial locations beyond its headquarters are not extensively detailed.
TRAW Corporate Image Assessment
The provided search results do not contain specific information about Traws Pharma, Inc.'s brand reputation in the past year or any events that have specifically affected it.
Ownership
The provided search results do not contain specific details about the major institutional and individual owners of Traws Pharma, Inc.
Ask Our Expert AI Analyst
Price Chart
$1.77
